The role of procalcitonin in the follow-up of medullary thyroid cancer
暂无分享,去创建一个
C. Mian | D. Basso | S. Censi | M. Iacobone | S. zovato | J. Manso | G. Crivellari | Alberto Mondin | F. Torresan | I. Piva | Teresa Benvenuti
[1] M. Hedayati,et al. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer. , 2021, Pathology, research and practice.
[2] L. Ceriani,et al. Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma. A meta-analysis. , 2021, The Journal of clinical endocrinology and metabolism.
[3] U. Pagotto,et al. Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows , 2021, Frontiers in Endocrinology.
[4] J. Kratzsch,et al. Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma , 2021, Clinical chemistry and laboratory medicine.
[5] G. Lippi,et al. Two-center comparison of 10 fully-automated commercial procalcitonin (PCT) immunoassays , 2019, Clinical chemistry and laboratory medicine.
[6] P. Trimboli,et al. Measuring procalcitonin to overcome heterophilic-antibody-induced spurious hypercalcitoninemia , 2018, Clinical chemistry and laboratory medicine.
[7] P. Trimboli,et al. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma , 2018, The International journal of biological markers.
[8] S. Barollo,et al. Calcitonin measurement and immunoassay interference: a case report and literature review , 2016, Clinical chemistry and laboratory medicine.
[9] P. Trimboli,et al. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature , 2015, Clinical chemistry and laboratory medicine.
[10] Douglas B. Evans,et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.
[11] M. Surks,et al. Medullary thyroid cancer with undetectable serum calcitonin. , 2015, The Journal of clinical endocrinology and metabolism.
[12] K. Lorenz,et al. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. , 2014, The Journal of clinical endocrinology and metabolism.
[13] R. Kurzrock,et al. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] A. Pinchera,et al. Advances in the follow-up of differentiated or medullary thyroid cancer , 2012, Nature Reviews Endocrinology.
[15] K. Nustad,et al. Heterophilic antibody interference in commercial immunoassays; a screening study using paired native and pre-blocked sera , 2011, Clinical chemistry and laboratory medicine.
[16] M. Walter,et al. Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer , 2009, Cancer.
[17] A. Algeciras-Schimnich,et al. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.
[18] H. Schneider,et al. Procalcitonin for the clinical laboratory: a review , 2007, Pathology.
[19] S. Hauptmann,et al. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. , 2007, Archives of surgery.
[20] F. Kraeber-Bodéré,et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. , 2005, The Journal of clinical endocrinology and metabolism.
[21] J. White,et al. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. , 2004, The Journal of clinical endocrinology and metabolism.
[22] E. Baudin,et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging , 2003, British Journal of Cancer.
[23] S. Baylin,et al. Changes in calcitonin gene RNA processing during growth of a human medullary thyroid carcinoma cell line. , 1989, Cancer research.
[24] B. Roos,et al. Human medullary thyroid carcinoma in culture provides a model relating growth dynamics, endocrine cell differentiation, and tumor progression. , 1984, The Journal of clinical endocrinology and metabolism.
[25] W. M. Linehan,et al. The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinoma , 1978, Cancer.
[26] David F Schneider,et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years , 2017, Surgery.
[27] R. Domingues,et al. Medullary thyroid carcinoma preferentially secreting procalcitonin. , 2014, Thyroid.
[28] P. Maruna,et al. Physiology and genetics of procalcitonin. , 2000, Physiological research.
[29] V. Rohmer,et al. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.